What is the conclusion of the committee regarding the use of bucindolol for heart failure-related exhaustion (HF-REF)?
The committee concluded that results of trials using Bucindolol should be excluded due to a lack of trial data suggesting prognostic benefit of bucindolol in patients with HF-REF, with respect to all-cause mortality. In addition, Bucindolol demonstrates pharmacogenetic differences in different ethnicities.